课题基金 / 基金详情

Isolation of PD-1 ligands and their application for immunosuppression

Isolation of PD-1 ligands and their application for immunosuppression
PD-1配体的分离及其在免疫抑制中的应用
批准号:
12557030
负责人:
HONJO Tasuku
金额:
$8.64万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2001

项目摘要

项目成果

HONJO Tasuku的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PD-1 -deficient mice develop a variety of autoimmune-like diseases, which suggests that this immunoinhibitory receptor plays an important role in tolerance. We identified PD-1 ligand 1 and 2 (PD-L1 and PD-L2) as ligands for PD-1 by computer-based homology search. Both ligands are expressed on nonlymphoid tissues, such as heart or liver. Engagement of PD-1 by PD-1 ligands leads to the inhibition of T cell receptor mediated lymphocyte proliferation and cytokine secretion. In addition, PD-1 signaling can inhibit at least suboptimal levels of CD28-mediated costimulation. PD-ligands are expressed by antigen-presenting cells, including human peripheral blood monocytes stimulated with interferon, and activated human and murine dendritic cells. Therefore, the relative levels of inhibitory PD-1 ligands and costimulatory B7-1/B7-2 signals on antigen presenting cells may determine the extent of lymphocyte activation and consequently the threshold between tolerance and autoimmunity.In addition, we … More also generated chimeric molecules composed of the IgG Fc receptor type IIB extracellular region and the PD-1 cytoplasmic region and expressed them in a B lymphoma cell line, IIA1.6. Coligation of the cytoplasmic region of PD-1 with the B cell receptor (BCR) in IIA1.6 transformants inhibited BCR-mediated growth retardation, and tyrosine phosphorylation of effector molecules, including Ig beta, Syk, phospholipase C-gamma 2 and ERK1/2. Mutagenesis studies indicated that these inhibitory effects do not require the N-terminal tyrosine in the immunoreceptor tyrosine-based inhibitory motif-like sequence, but do require the other tyrosine residue in the C-terminal tail. This tyrosine was phosphorylated and recruited src homology 2-domain-containing tyrosine phosphatase 2 (SHP-2) on cologation of PD-1 with BCR. These results show that PD-1 can inhibit BCR signaling by recruiting SHP-2 to its phosphotyrosine and dephosphorylating key signal transducers of BCR signaling.Taken together, we identified two PD-1 ligands and showed that the inhibitory signal of PD-1 is mediated by SHP-2. Less
期刊论文(30)
专著(0)
科研奖励(0)
会议论文
Carter, L. et al.: "PD-1: PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2"Eur. J. Immunol.. 32. 634-643 (2002)
Carter, L. 等人:“PD-1:PD-L 抑制途径影响 CD4( ) 和 CD8( ) T 细胞,并被 IL-2 克服”Eur。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Okazaki, T., Maeda, A., Nishimura, H., Honjo, T.: "PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting Src homology2-domain-containing tyrosine phospatase 2 to phosphotyrosine"Proc.Natl.Acad.Sci.USA. 98. 13866-13871 (2001)
Okazaki, T.、Maeda, A.、Nishimura, H.、Honjo, T.:“PD-1 免疫受体通过将包含 Src 同源 2 结构域的酪氨酸磷酸酶 2 募集到磷酸酪氨酸来抑制 B 细胞受体介导的信号传导”Proc.Natl。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Okazaki, T. et al.: "PD-1 immunoreceptor inhibits B cell receptor mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine"Proc. Natl. Acad. Sci. USA. 98. 13866-13871 (2001)
Okazaki, T. 等人:“PD-1 免疫受体通过将包含 src 同源 2 结构域的酪氨酸磷酸酶 2 募集到磷酸酪氨酸来抑制 B 细胞受体介导的信号传导”Proc.
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
14
    Mechanism for genome instability by activation induced cytidine deaminase induced-reduction of topoisomerase1
    • 批准号:
      22000015
    • 项目类别:
      Grant-in-Aid for Specially Promoted Research
    • 资助金额:
      $285.54万
    • 财政年份:
      2010
    • 负责人:
      HONJO Tasuku
    • 依托单位:
    AID-dependent genetic alteration mechanism to generate antigen-specific antibodies
    • 批准号:
      17002015
    • 项目类别:
      Grant-in-Aid for Specially Promoted Research
    • 资助金额:
      $489.22万
    • 财政年份:
      2005
    • 负责人:
      HONJO Tasuku
    • 依托单位:
    Regulation of lymphocyte development by Notch/RBP-J signaling
    • 批准号:
      16209018
    • 项目类别:
      Grant-in-Aid for Scientific Research (A)
    • 资助金额:
      $21.96万
    • 财政年份:
      2004
    • 负责人:
      HONJO Tasuku
    • 依托单位:
    Molecular analysis of TSK mouseas a model of scleroderma
    • 批准号:
      10044275
    • 项目类别:
      Grant-in-Aid for Scientific Research (B).
    • 资助金额:
      $4.54万
    • 财政年份:
      1998
    • 负责人:
      HONJO Tasuku
    • 依托单位:
    国内基金
    海外基金
    基于PD-L1/PD-1通路探讨标本配穴电针调控Th17/Treg平衡改善肥胖胰岛素抵抗的作用机制
    • 批准号:
      JCZRLH202600504
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
    • 依托单位:
    基于PD-1/PD-L1调控PI3K/AKT与MAPK/ERK通路探讨栀子苷-大黄素配伍改善脓毒症免疫抑制的作用
    • 批准号:
      2026JJ81015
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      谢伶俐
    • 依托单位:
    具核梭杆菌通过PD-1/PD-L1通路调控牙周炎免疫微环境的机制与干预研究
    • 批准号:
      2026JJ81697
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      赵丹唯
    • 依托单位:
    基于多模态影像组学的PD-1/PD-L1抑制剂敏感性乳腺癌患者智能筛选与疗效预测研究
    • 批准号:
      2026JJ82702
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      蒋忠军
    • 依托单位: